Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
5000
百万円（営業利益・税引前四半期利益）Wording
Conditional
How definitive the wording is.Revised forecast
Fiscal year ended March 2023 · Cumulative second quarterPrevious forecast published 2022年5月11日Net Sales67,000→71,000million
+6.0%
Operating profit14,500→19,500million
+34.5%
Profit attributable to owners of the parent11,300→15,500million
+37.2%
Net income per share167.77→230.13yen and sen
+37.2%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
国内医薬品、ビルテプソ米国売上、機能食品事業が好調に推移し、売上収益は当初予想を40億円上回る見込み。利益は増収に加え、研究開発費が当初予想を下回り、為替差益が大きく発生する見込みとなったため。
Previous-period results売上収益 71,568百万円、営業利益 21,504百万円、税引前四半期利益 22,250百万円、親会社の所有者に帰属する四半期利益 16,561百万円、基本的1株当たり四半期利益 245.89円銭（2022年3月期第2四半期、日本基準）
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥67,000 million → ¥71,000 million（+6.0%） |
| Operating profit | ¥14,500 million → ¥19,500 million（+34.5%） |
| Profit attributable to owners of the parent | ¥11,300 million → ¥15,500 million（+37.2%） |
| Net income per share | 167.77 yen and sen → 230.13 yen and sen |
| Fiscal Period Covered | Fiscal year ended March 2023 |
| Period Covered | Cumulative second quarter |
| Publication date of previous forecast | 2022年5月11日 |
| Previous-period results | 売上収益 71,568百万円、営業利益 21,504百万円、税引前四半期利益 22,250百万円、親会社の所有者に帰属する四半期利益 16,561百万円、基本的1株当たり四半期利益 245.89円銭（2022年3月期第2四半期、日本基準） |
| Reason for the revision | 国内医薬品、ビルテプソ米国売上、機能食品事業が好調に推移し、売上収益は当初予想を40億円上回る見込み。利益は増収に加え、研究開発費が当初予想を下回り、為替差益が大きく発生する見込みとなったため。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Ordinary incomeDetails and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.国内医薬品、ビルテプソの米国売上、機能食品事業が好調に推移したことに加え、研究開発費が当初予想を下回り、為替差益も大きく発生する見込みとなったため。通期の連結業績予想は現在精査中で、2022年11月10日予定の第2四半期決算発表時に公表するとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.